Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.
Gate Bioscience has raised $65.0M in total funding. The most recent round was Series B. The last funding was announced in November 2025.
Gate Bioscience's investors include Andreessen Horowitz, ARCH Venture Partners, Eli Lilly, Forbion Capital Partners, Versant Ventures.
Gate Bioscience is headquartered in Brisbane, United States.
Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.
Gate Bioscience is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gate Bioscience — Funding & Investors." VCBacked, November 13, 2025, https://www.vcbacked.co/company/gate-bioscience. Accessed September 13, 2026.
VCBacked. (2025). Gate Bioscience — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/gate-bioscience
{{cite web |title=Gate Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/gate-bioscience |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated